Chester County News and Community Website
PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) will present new preclinical data on DNA-based protein therapies for hemophilia at the World Federation of Hemophilia World Congress in Kuala Lumpur on …
INOVIO to Present Hemophilia Research at Global Conference Read More PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) reported its 2025 financial results and said the U.S. Food and Drug Administration is reviewing its lead drug candidate, INO-3107, for a rare …
INOVIO Reports 2025 Results as FDA Reviews Lead Drug Candidate Read More PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) said it will present research on its DNA-based therapies at two upcoming scientific conferences in Europe and the United States.
INOVIO to Present DNA Medicine Data at Two Scientific Conferences Read More PLYMOUTH MEETING, PA — INOVIO and Akeso, Inc. announced a clinical trial collaboration to evaluate a combination immunotherapy as a potential treatment for Glioblastoma, the most common and aggressive form …
INOVIO and Akeso Partner to Study New Glioblastoma Therapy Read More PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) announced that it will participate in several upcoming scientific and investor conferences in February and March.
INOVIO to Present at Cancer, Investor Conferences Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) said the U.S. Food and Drug Administration has accepted its Biologics License Application for INO-3107, a potential non-surgical treatment for adults with recurrent …
FDA Sets 2026 Decision Clock for INOVIO’s Rare Disease Therapy Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) said it has granted an equity award to a newly hired employee under its 2022 Inducement Plan, a move commonly used by public …
INOVIO Issues Equity Award to New Hire as It Rebuilds for Its Next Act Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) will present at two major investor conferences in December, setting the stage for fresh attention on the company’s DNA medicine pipeline as markets …
INOVIO Maps Out High-Stakes December as Investors Eye Rare Disease Catalysts Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) reported third-quarter 2025 results and detailed a series of regulatory and clinical milestones that could reshape the company’s trajectory as it moves closer …
INOVIO Advances Toward First Commercial Product as BLA Filing Caps Pivotal Quarter Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced that it has completed the rolling submission of its Biologics License Application (BLA) for INO-3107, a DNA-based immunotherapy candidate for adults with …
INOVIO Submits FDA Application for First DNA Therapy to Treat Rare HPV Disease Read More